Cargando...
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...
Gardado en:
| Publicado en: | Eur J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/ https://ncbi.nlm.nih.gov/pubmed/31838747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|